6HN3
![Download](https://newweb-cs.pages.dev/newweb/media/icons/dl.png) ![Visualize](https://newweb-cs.pages.dev/newweb/media/icons/hoh_3d.png)
![BU of 6hn3 by Molmil](/molmil-images/mine/6hn3) | wildtype form (apo) of human GPX4 with Se-Cys46 | 分子名称: | CHLORIDE ION, ETHANOL, GLYCEROL, ... | 著者 | Hillig, R.C, Moosmayer, D, Hilpmann, A, Hoffmann, J, Schnirch, L, Eaton, J.K, Badock, V, Gradl, S. | 登録日 | 2018-09-13 | 公開日 | 2020-04-01 | 最終更新日 | 2024-01-24 | 実験手法 | X-RAY DIFFRACTION (1.01 Å) | 主引用文献 | Crystal structures of the selenoprotein glutathione peroxidase 4 in its apo form and in complex with the covalently bound inhibitor ML162. Acta Crystallogr D Struct Biol, 77, 2021
|
|
6HKQ
![Download](https://newweb-cs.pages.dev/newweb/media/icons/dl.png) ![Visualize](https://newweb-cs.pages.dev/newweb/media/icons/hoh_3d.png)
![BU of 6hkq by Molmil](/molmil-images/mine/6hkq) | Human GPX4 in complex with covalent Inhibitor ML162 (S enantiomer) | 分子名称: | (2~{S})-2-[2-chloranylethanoyl-(3-chloranyl-4-methoxy-phenyl)amino]-~{N}-(2-phenylethyl)-2-thiophen-2-yl-ethanamide, 1,2-ETHANEDIOL, DIMETHYL SULFOXIDE, ... | 著者 | Hillig, R.C, Moosmayer, D, Hilpmann, A, Hoffmann, L, Schnirch, L, Eaton, J.K, Badock, V, Gradl, S. | 登録日 | 2018-09-07 | 公開日 | 2020-04-01 | 最終更新日 | 2022-12-07 | 実験手法 | X-RAY DIFFRACTION (1.54 Å) | 主引用文献 | Crystal structures of the selenoprotein glutathione peroxidase 4 in its apo form and in complex with the covalently bound inhibitor ML162. Acta Crystallogr D Struct Biol, 77, 2021
|
|
6QU7
![Download](https://newweb-cs.pages.dev/newweb/media/icons/dl.png) ![Visualize](https://newweb-cs.pages.dev/newweb/media/icons/hoh_3d.png)
![BU of 6qu7 by Molmil](/molmil-images/mine/6qu7) | Crystal structure of human DHODH in complex with BAY 2402234 | 分子名称: | ACETATE ION, Dihydroorotate dehydrogenase (quinone), mitochondrial, ... | 著者 | Friberg, A, Gradl, S. | 登録日 | 2019-02-26 | 公開日 | 2019-06-05 | 最終更新日 | 2024-05-15 | 実験手法 | X-RAY DIFFRACTION (1.52 Å) | 主引用文献 | The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. Leukemia, 33, 2019
|
|